Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis (CRCRT-EC)

February 1, 2012 updated by: Centre Oscar Lambret

Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer

The aim of this study is to identify prognostic factors for outcome in patients being complete clinical responders with chemoradiation or radiation for esophageal cancer

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France, 59000
        • Centre OSCAR LAMBRET

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient treated for esophageal cancer in the Northern France Cancer Center from january 1998 to december 2003

Description

Inclusion Criteria:

  • localized or locally advanced esophageal cancer
  • patient who underwent definite chemoradiation or radiation
  • patient with complete clinical response

Exclusion Criteria:

  • metastatic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification of prognostic factors for overall survival
Time Frame: From date of treatment until death, assessed up to 10 years
Correlation between survival and baseline,clinical and treatment characteristics
From date of treatment until death, assessed up to 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patterns of treatment failure
Time Frame: From date of treatment until treatment failure, assessed up to 10 years
Type of recurrence : local, regional, distant.
From date of treatment until treatment failure, assessed up to 10 years
Disease-free survival
Time Frame: From date of treatment until progression or death, assessed up to 10 years
Time between the end of treatment and the occurence of progression
From date of treatment until progression or death, assessed up to 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Oscar Lambret

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

January 1, 2012

Study Completion (Actual)

January 1, 2012

Study Registration Dates

First Submitted

January 30, 2012

First Submitted That Met QC Criteria

February 1, 2012

First Posted (Estimate)

February 3, 2012

Study Record Updates

Last Update Posted (Estimate)

February 3, 2012

Last Update Submitted That Met QC Criteria

February 1, 2012

Last Verified

February 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CRCRT-EC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Cancer

Clinical Trials on Chemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe